Nonsurgical septal reduction therapy significantly decreased left ventricular mass from 301 g at baseline to 190 g at 2 years (P<0.01) in patients with hypertrophic obstructive cardiomyopathy.
Cohort (n=26)
Does nonsurgical septal reduction therapy with intracoronary ethanol reduce left ventricular mass and outflow tract gradient in patients with hypertrophic obstructive cardiomyopathy?
Nonsurgical septal reduction therapy with intracoronary ethanol induces favorable long-term left ventricular remodeling, significantly reducing LV mass and outflow tract gradient at 2 years.
Absolute Event Rate: 190% vs 301%
p-value: p=<0.01
BACKGROUND: Hypertrophic obstructive cardiomyopathy (HOCM) is characterized by left ventricular hypertrophy (LVH) in the absence of increased external load. Recently, nonsurgical septal reduction therapy (NSRT) with intracoronary ethanol has been introduced to treat severely symptomatic patients with outflow tract obstruction. Its long-term effects on LV mass, however, are unknown. METHODS AND RESULTS: The LV size, function, and outflow tract gradient of 26 HOCM patients (53+/-15 years old) who underwent NSRT were assessed by echocardiography at baseline and 1 and 2 years after the procedure. LVH was evaluated by wall thickness of individual myocardial segments, planimetered myocardial area, and mass. The outflow gradient decreased from 36+/-6 mm Hg before NSRT to 0+/-3 mm Hg at 2 years (P<0.001), with patients experiencing symptomatic improvement (P<0.05). LV end-diastolic and end-systolic dimensions increased significantly at both 1 and 2 years (P<0.001). All parameters of LVH showed evidence of regression. LV mass decreased (301+/-78 g at baseline, 223+/-5 g at 1 year, and 190+/-58 g at 2 years; P<0.01), with the 2-year reduction in mass related to infarct size and the acute reduction in outflow tract gradient (r=0.48, P<0.05 and r=0.63, P<0.01, respectively). CONCLUSIONS: NSRT results in LV remodeling that is characterized by an increase in LV size and a decrease in the extent of LVH.
Mazur et al. (Tue,) conducted a cohort in Hypertrophic obstructive cardiomyopathy (HOCM) (n=26). Nonsurgical septal reduction therapy (NSRT) with intracoronary ethanol vs. Baseline was evaluated on Left ventricular mass (p=<0.01). Nonsurgical septal reduction therapy significantly decreased left ventricular mass from 301 g at baseline to 190 g at 2 years (P<0.01) in patients with hypertrophic obstructive cardiomyopathy.